compensation information for gillian c iversread  evp of technical operations and chief regulatory officer of clovis oncology inc  salarycom enterprise small business personal contact us log in salaries jobs education advice gillian c iversread executive compensation as evp of technical operations and chief regulatory officer at clovis oncology inc gillian c iversread made  in total compensation of this total  was received as a salary  was received as a bonus  was received in stock options  was awarded as stock and  came from other types of compensation this information is according to proxy statements filed for the  fiscal year enter an executive or company name new search go the chart on this page features a breakdown of the total annual pay for gillian c iversread  evp of technical operations and chief regulatory officer at clovis oncology inc as reported in their proxy statements total cash compensation information is comprised of yearly base pay and bonuses clovis oncology inc income statements for executive base pay and bonus are filed yearly with the sec in the edgar filing system clovis oncology inc annual reports of executive compensation and pay are most commonly found in the def a documents total equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year other compensation covers all compensationlike awards that dont fit in any of these other standard categories numbers reported do not include change in pension value and nonqualified deferred compensation earnings other executives at this company erle t mast patrick j mahaffy lindsey rolfe c dale hooks daniel w muehl gillian c iversread base pay bonus  incentive comp total cash compensation stock award value option award value total equity total other total compensation browse executives by first name a b c d e f g h i j k l m n o p q r s t u v w x y z browse companies by company name a b c d e f g h i j k l m n o p q r s t u v w x y z  this report is not for commercial use thorough reviews have been conducted to assure this data accurately reflects disclosures however for a complete and definitive understanding of the pay practices of any company users should refer directly to the actual complete proxy statement use of data  disclaimer the information shown here is a reporting of information included in the companys proxy statement the proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information for those interested in conducting a detailed compensation analysis we recommend that you review the entire proxy statement you may retrieve the full proxy statement by going to the securities and exchange commission sec website at wwwsecgov and entering the companys name and then looking in the first column for an entry of form def a or any similar code you may also find the annual proxy statement by going directly to the companys website what is a proxy statement a proxy statement or proxy is a form that every publicly traded us company is required to file with the us securities  exchange commission sec within  days after the end of its fiscal year the proxy must be sent to every shareholder in advance of the companys annual shareholders meeting all proxy statements are public filings made available to the general public by the sec the proxy statements main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting including decisions such as electing directors ratifying the selection of auditors and other shareholderrelated decisions including shareholderinitiated initiatives also proxies must disclose specific detailed information regarding the pay practices for certain executives       privacy policy terms of use about us contact us  salarycom all rights reserved us salaries canadian salaries purchase a salary report salaries by category salaries by income salaries by industry popular salaries negotiation tips benefits calculator search job openings job openings by state job openings by category education by career education by level education by major cost of living calculator gillian c iversread  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in gillian c iversread see remarks at clovis oncology inc view full profile are you gillian c iversread claim your profile   sign up for equilar atlas and view gillian c iversreads full profile with equilar atlas you can identify corporate executives in gillian c iversreads network and community follow changes in gillian c iversreads employment and moneyinmotion connect with gillian c iversread through your network of contacts gillian c iversreads executive work history current see remarks clovis oncology inc past to view gillian c iversreads complete executive work history sign up now education bs university college london age      gillian c iversreads biography gillian c iversread is one of our cofounders and has served as our executive vice president of technical operations and chief regulatory officer since our inception previously ms iversread served as executive vice president development operations at pharmion corporation acquired in  beginning in  from  to  ms iversread held various regulatory positions with hoechst marion roussel and its successor aventis pharmaceuticals inc where she most recently held the position of vice president global regulatory affairs from  to  ms iversread was vice president development and regulatory affairs for argus  read more gillian c iversread is one of our cofounders and has served as our executive vice president of technical operations and chief regulatory officer since our inception previously ms iversread served as executive vice president development operations at pharmion corporation acquired in  beginning in  from  to  ms iversread held various regulatory positions with hoechst marion roussel and its successor aventis pharmaceuticals inc where she most recently held the position of vice president global regulatory affairs from  to  ms iversread was vice president development and regulatory affairs for argus pharmaceuticals and from  to  she served as a regulatory affairs director for marion merrell dow ms iversread received a bsc in pharmacology from university college london source clovis oncology inc on    sign up for equilar atlas and view gillian c iversreads full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like gillian c iversread more specifically youll be able to identify corporate executives in gillian c iversreads network and community follow changes in gillian c iversreads employment and moneyinmotion connect with gillian c iversread through your network of conections view full profile   search for over  executive profiles bio example gillian c iversread gillian c iversreads connections  sign up now to view gillian c iversreads  connections » james c blair former board member clovis oncology inc james j loughlin board member celgene corporation michael d casey lead independent director celgene corporation ramesh subrahmanian former advisor stryker corporation gilla kaplan board member celgene corporation keith t flaherty board member loxo oncology inc robert j hugin executive chairman celgene corporation erle t mast former board member zogenix inc patrick j mahaffy dir president and chief executive officer clovis oncology inc john r leone chairman of the board windtree therapeutics inc popular profiles sign up now to view more executive profiles » john j kita evp and cfo a o smith elon r musk ceo and chairman tesla thomas j lynch executive chairman te connectivity ltd jan koum board member facebook inc robert d perlmutter senior evp and coo the macerich company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   gillian c iversread bsc executive profile  biography  bloomberg july    pm et biotechnology company overview of clovis oncology inc snapshotpeople  overviewboard memberscommittees executive profile gillian c iversread bsccofounder chief regulatory officer and executive vice president of technical operations clovis oncology incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriesas of fiscal year  background dr gillian c iversread bsc cofounded clovis oncology inc on april   and has been its chief regulatory officer and executive vice president of technical operations since april   previously dr iversread served as an executive vice president of development operations at pharmion corpand pharmion llc since august  she served as a vice president of clinical development and regulatory affairs at pharmion corp since april  and also served  as its executive vice president of clinical development regulatory affairs  medical since february   from  to  dr iversread held various regulatory positions with hoechst marion roussel and its successor aventis pharmaceuticals inc where she served as a vice president of global regulatory affairs from  to  she served as vice president of development and regulatory affairs at argus pharmaceuticals and from  to  she served as a regulatory affairs director of marion merrell dow she served as a director of biopath holdings inc from  to october   and also served as its scientific advisor until october   ms iversread holds a bs with honors from university college london in pharmacologyread full background corporate headquarters  flatiron parkwayboulder colorado united statesphone fax  board members memberships there is no board members memberships data available education bs university college london other affiliations pharmion llcuniversity college londonbiopath holdings inc annual compensation salarybonustotal annual compensation stocks options restricted stock awardsall other compensationexercisable optionsexercisable options valueunexercisable optionsunexercisable options valuetotal value of optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact clovis oncology inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close clovis oncology inc clvs rating increased to buy at zacks investment research  daily political home aboutcontact columnists privacy policy headlines politics nation world issues economy finance clovis oncology inc  get news  ratings daily enter your email address below to get the latest news and analysts ratings for clovis oncology inc with our free daily email newsletter follow dailypolitical     latest news syneron medical ltd nasdaqelos shares sold by dalton greiner hartman maher  co fidelity national information services inc nysefis position increased by state treasurer state of michigan dalton greiner hartman maher  co takes position in abm industries incorporated nyseabm state treasurer state of michigan continues to hold position in exelon corporation nyseexc wesbanco inc nasdaqwsbc position decreased by dalton greiner hartman maher  co dalton greiner hartman maher  co cuts position in deckers outdoor corporation nysedeck party city holdco inc nyseprty shares sold by peregrine capital management llc servisfirst bancshares inc nasdaqsfbs shares sold by peregrine capital management llc  shares in forward air corporation nasdaqfwrd acquired by dalton greiner hartman maher  co dalton greiner hartman maher  co buys shares of  ttm technologies inc nasdaqttmi dalton greiner hartman maher  co cuts stake in analog devices inc nasdaqadi cyberark software ltd nasdaqcybr shares sold by peregrine capital management llc virtu financial inc nasdaqvirt shares sold by peregrine capital management llc douglas lane  associates llc boosts position in marsh  mclennan companies inc nysemmc swift transportation company nyseswft shares sold by peregrine capital management llc peregrine capital management llc has  million stake in kar auction services inc nysekar peregrine capital management llc decreases position in formfactor inc nasdaqform chipotle mexican grill inc nysecmg stake increased by douglas lane  associates llc copa holdings sa nysecpa shares bought by highland capital management llc douglas lane  associates llc purchases  shares of zions bancorporation nasdaqzion clovis oncology inc clvs rating increased to buy at zacks investment research july th    comments  filed under  by patrick bannon filed under analyst articles  us  finance tweet clovis oncology inc nasdaqclvs was upgraded by zacks investment research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on wednesday the firm currently has a  price objective on the biopharmaceutical company’s stock zacks investment research‘s price target points to a potential upside of  from the company’s previous close according to zacks “clovis got a huge boost with the fda granting accelerated approval to its advanced ovarian cancer treatment rubraca in dec  rubraca has bright prospects given the tremendous demand for parp inhibitors successful commercialization will significantly boost clovis’ sales rubraca is also under review in the eu for a comparable indication several studies on rubraca targeting different types of ovarian cancer patients are currently underway promising progressionfree survival and safety results from the ariel maintenance study will help expand rubraca’s label thereby improving the commercial uptake of the drug clovis’ heavy dependence on rubraca the only approved product for growth is concerning rubraca is set to face intense competition from currently marketed parp inhibitors loss estimates have widened lately ahead of the q results clovis has a mixed earnings surprise record in the recent quarters” clvs has been the subject of a number of other research reports piper jaffray companies set a  target price on shares of clovis oncology and gave the stock a “buy” rating in a report on tuesday march th morgan stanley reiterated an “overweight” rating and issued a  price objective on shares of clovis oncology in a report on tuesday may nd valuengine upgraded shares of clovis oncology from a “sell” rating to a “hold” rating in a report on friday june nd goldman sachs group inc the raised their price objective on shares of clovis oncology from  to  and gave the company a “neutral” rating in a report on wednesday march th finally credit suisse group reiterated an “outperform” rating and issued a  price objective on shares of clovis oncology in a report on friday june th seven analysts have rated the stock with a hold rating twelve have assigned a buy rating and one has given a strong buy rating to the company the company presently has a consensus rating of “buy” and an average price target of  shares of clovis oncology nasdaqclvs traded up  during trading on wednesday hitting   shares of the company’s stock were exchanged the stock’s market cap is  billion the stock’s day moving average price is  and its day moving average price is  clovis oncology has a year low of  and a year high of  clovis oncology nasdaqclvs last posted its earnings results on wednesday may rd the biopharmaceutical company reported  eps for the quarter topping analysts’ consensus estimates of  by  the company had revenue of  million during the quarter compared to the consensus estimate of  million on average equities analysts expect that clovis oncology will post  earnings per share for the current fiscal year illegal activity warning “clovis oncology inc clvs rating increased to buy at zacks investment research” was first posted by daily political and is owned by of daily political if you are reading this news story on another domain it was stolen and reposted in violation of us  international trademark  copyright law the original version of this news story can be accessed at httpswwwdailypoliticalcomclovisoncologyincclvsratingincreasedtobuyatzacksinvestmentresearchhtml in related news insider gillian c iversread sold  shares of the business’s stock in a transaction dated thursday june th the stock was sold at an average price of  for a total value of  following the sale the insider now directly owns  shares in the company valued at approximately  the sale was disclosed in a document filed with the securities  exchange commission which is available at this hyperlink insiders have sold a total of  shares of company stock worth  over the last quarter company insiders own  of the company’s stock a number of large investors have recently made changes to their positions in the stock two sigma investments lp purchased a new stake in shares of clovis oncology during the fourth quarter worth about  guggenheim capital llc purchased a new stake in shares of clovis oncology during the fourth quarter worth about  frontier capital management co llc purchased a new stake in shares of clovis oncology during the first quarter worth about  norges bank purchased a new stake in shares of clovis oncology during the fourth quarter worth about  finally renaissance technologies llc purchased a new stake in shares of clovis oncology during the fourth quarter worth about  institutional investors and hedge funds own  of the company’s stock about clovis oncology clovis oncology inc is a biopharmaceutical company focused on acquiring developing and commercializing anticancer agents in the united states europe and other international markets the company’s product candidates include rociletinib rubraca rucaparib and lucitanib rucaparib is an oral small molecule poly adenosine diphosphate adpribose polymerase parp inhibitor of parp parp and parp approved as a monotherapy for the treatment of patients with deleterious breast cancer brca human genes associated with the repair of damaged deoxyribonucleic acid dna mutation germline andor somatic associated advanced ovarian cancer get a free copy of the zacks research report on clovis oncology clvs for more information about research offerings from zacks investment research visit zackscom receive news  ratings for clovis oncology inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for clovis oncology inc and related companies with marketbeatcoms free daily email newsletter  comment on this post click here to cancel reply name required mail will not be published required website wordpress hashcash needs javascript to work but your browser has javascript disabled your comment will be placed in moderation latest news jeff sessions spoke of resigning after tensions increase with trump president trump’s tweets complicate already complicated week world leaders very critical of paris agreement decision by trump aide to president trump resigns with more expected scudclass missile launched by north korea  dailypolitical llc  all rights reserved privacy policy  about  columnists  contact ﻿ clovis oncology clvs earns coverage optimism rating of   markets daily daily ratings  news for clovis oncology inc complete the form below to receive the latest headlines and analysts recommendationsfor clovis oncology inc with our free daily email newsletter follow themarketsdaily the markets daily recent posts atria investments llc sells  shares of alexandria real estate equities inc are clovis oncology clvs earns coverage optimism rating of  hillrom holdings inc nysehrc position raised by public employees retirement system of ohio paloma partners management co acquires shares of  sociedad quimica y minera sa nysesqm schroder oriental income fund limited soi insider purchases £ in stock american eagle outfitters inc nyseaeo downgraded by bidaskclub atria investments llc purchases new stake in silicon motion technology corporation nasdaqsimo ralph lauren corporation rl shares sold by nomura asset management co ltd polaris industries inc nysepii stake raised by xact kapitalforvaltning ab amalgamated bank sells  shares of neogen corporation neog paloma partners management co increases stake in autonation inc nysean aptargroup inc atr stake cut by teachers retirement system of the state of kentucky ix lp mdv sells  shares of coupa software nasdaqcoup stock blackrock inc has  million position in legacytexas financial group inc nasdaqltxb ubs group ag sells  shares of glacier bancorp inc gbci nuveen asset management llc has  million position in brookfield renewable partners lp bep xact kapitalforvaltning ab invests  million in commscope holding company inc nasdaqcomm financial comparison calithera biosciences cala versus adma biologics nasdaqadma motorcar parts of america inc mpaa receives new coverage from analysts at fbr  co zacks brokerages expect rexnord corporation nyserxn to announce  earnings per share clovis oncology clvs earns coverage optimism rating of  posted by sarita garza on jul th   no comments news coverage about clovis oncology nasdaqclvs has been trending somewhat positive on tuesday according to accern sentiment analysis accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in realtime accern ranks coverage of public companies on a scale of negative one to positive one with scores closest to one being the most favorable clovis oncology earned a news sentiment score of  on accern’s scale accern also assigned media headlines about the biopharmaceutical company an impact score of  out of  indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term here are some of the media headlines that may have effected accern sentiment’s analysis get clovis oncology inc alerts are clovis oncology inc nasdaqclvs or wintrust financial corporation nasdaqwtfc ready to rumble – flbc news flbcnewscom clovis oncology inc nasdaqclvs insider gillian c iversread sells  shares americanbankingnewscom clovis oncology inc clvs noted a price change of  and becton dickinson and company bdx closes with a … – stocks gallery stocksgallerycom the clovis oncology sees unusually large options volume clvs wpsuperfanboycom are analysts bearish clovis oncology inc nasdaqclvs after last week campdesrecruescom shares of clovis oncology clvs opened at  on tuesday the stock has a  day moving average price of  and a  day moving average price of  clovis oncology has a year low of  and a year high of  the firm’s market capitalization is  billion clovis oncology nasdaqclvs last announced its quarterly earnings results on wednesday may rd the biopharmaceutical company reported  earnings per share eps for the quarter topping the consensus estimate of  by  the company had revenue of  million for the quarter compared to analyst estimates of  million equities research analysts anticipate that clovis oncology will post  earnings per share for the current fiscal year clvs has been the subject of a number of recent analyst reports j p morgan chase  co raised clovis oncology from a “neutral” rating to an “overweight” rating and set a  price target for the company in a report on wednesday may th valuengine cut clovis oncology from a “hold” rating to a “sell” rating in a report on friday may th cann initiated coverage on clovis oncology in a report on thursday june nd they set a “market perform” rating for the company bank of america corporation reaffirmed a “buy” rating and set a  price target on shares of clovis oncology in a report on wednesday may th finally credit suisse group reaffirmed an “outperform” rating and set a  price target on shares of clovis oncology in a report on tuesday april th eight equities research analysts have rated the stock with a hold rating eleven have given a buy rating and one has given a strong buy rating to the company’s stock the company presently has an average rating of “buy” and an average price target of  copyright violation notice “clovis oncology clvs earns coverage optimism rating of ” was originally published by markets daily and is the sole property of of markets daily if you are accessing this story on another website it was illegally copied and republished in violation of united states  international trademark  copyright legislation the correct version of this story can be accessed at httpswwwthemarketsdailycomclovisoncologyclvsearnscoverageoptimismratingofhtml in other news insider gillian c iversread sold  shares of the company’s stock in a transaction on monday may th the shares were sold at an average price of  for a total transaction of  following the completion of the transaction the insider now directly owns  shares in the company valued at  the sale was disclosed in a document filed with the securities  exchange commission which can be accessed through this link insiders have sold  shares of company stock valued at  over the last quarter company insiders own  of the company’s stock about clovis oncology clovis oncology inc is a biopharmaceutical company focused on acquiring developing and commercializing anticancer agents in the united states europe and other international markets the company’s product candidates include rociletinib rubraca rucaparib and lucitanib rucaparib is an oral small molecule poly adenosine diphosphate adpribose polymerase parp inhibitor of parp parp and parp approved as a monotherapy for the treatment of patients with deleterious breast cancer brca human genes associated with the repair of damaged deoxyribonucleic acid dna mutation germline andor somatic associated advanced ovarian cancer receive news  ratings for clovis oncology inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for clovis oncology inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website form  clovis oncology inc for mar  filed by iversread gillian c research stocks news story skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  news  events  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print format change text size default text sizea larger text sizea largest text sizea form  clovis oncology inc for mar  filed by iversread gillian c by k wizard—  pm et  httparchivefastedgarcomaczwzsczzzozztmqzrz filed on march   more clvs news clvs has no more news copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top sbgi log in for events holx caty gmed aehr pbf log in for events ryi tier etm sons find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  pm et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  clvs stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsclvs clovis oncology inc    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all clovis oncology to announce second quarter  financial results and host webcast conference call on august  business wire –  am et  clovis oncology inc clvs will announce its second quarter  financial results on wednesday august   after the close of the us financial markets the conference call is being webcast and can be accessed from the clovis oncology clvs website at wwwclovisoncologycom conference call details clovis will hold a conference call to discuss second quarter  results on august  at  pm et briefclovis oncology announces underwriters option to purchase additional shares reuters –  pm et  clovis oncology inc clvs  clovis oncology clvs announces exercise in full of underwriters option to purchase additional shares of common stock source text for eikon further company coverage clovis oncology announces exercise in full of underwriters’ option to purchase additional shares of common stock business wire –  pm et  clovis oncology inc clvs announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional  shares the offering including the sale of the additional shares is expected to close on june   subject to customary closing conditions healthcare stocks rally as senate set to unveil bill reuters –  pm et  as the us senate plans to unveil its bill to alter the healthcare system stocks in the sector have been on a roll led by biotechnology shares the sp  healthcare sector has topped all other major groups this month and led the way again on wednesday biopharma stock breakouts with significant developments and market activity pr newswire –  pm et  palm beach florida june   as the markets head into the typical summer slowdown period a few pharma and biotech stocks are putting up impressive performances today such as moleculin biotech inc mbrx exelixis inc exel immunogen inc imgn epizyme inc epzm and clovis oncology inc moleculin biotech mbrx inc  was up over  in morning trading today reaching  on over  million shares traded by the dark side of good news in biotech marketwatch –  am et  deal making is a staple of the biotech industry but betting on mergers and acquisitions is much harder than it looks for investors fresh cancer data from clovis oncology clvs illustrate this point the company announced monday that its latestage clinical trial for cancer treatment rubraca was a success in patients with ovarian cancer key pharma stocks with advanced developments and breakthrough discoveries pr newswire –  am et  palm beach florida june   the biotech and pharma industries experienced a rather tough  mainly due to the political uncertainty affecting the drug pricing controversy but some key companies have seemed to bounced back somewhat this year with the nyse arca pharmaceutical index gaining  yeartodate briefclovis oncology announces upsizing and pricing of public offering reuters –  pm et  clovis oncology inc clvs  clovis oncology clvs announces upsizing and pricing of public offering of common stock  size of offering was upsized from  million to  million  clovis oncology inc clvs says priced underwritten public offering of  million shares of its common stock at  per share source text for eikon further company coverage clovis oncology announces upsizing and pricing of public offering of common stock business wire –  pm et  clovis oncology inc clvs announced today the pricing of an underwritten public offering of  shares of its common stock at  per share before underwriting discounts and commissions the offering is expected to close on june   subject to customary closing conditions clovis oncology stock price target raised to  from  at jp morgan marketwatch –  am et  us stockswall st hits record highs on strong technology health stocks reuters –  pm et   feds dudley says tight labor market should push inflation up  biogen clovis boost healthcare indexes  investors flood back to technology  indexes up dow  pct sp  pct nasdaq  pct by sinead carew briefclovis oncology announces proposed offering of common stock reuters –  pm et  clovis oncology inc clvs  clovis oncology clvs announces proposed offering of common stock  clovis oncology inc clvs  commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately  million clovis oncology to launch  mln stock offering marketwatch –  pm et  clovis oncology inc clvs said on monday it plans to launch a  million stock offering the announcement follows a  surge in clovis oncology clvs shares after the company released positive latestage trial results for cancer drug rubraca the stock offering proceeds will be used for various general purposes including sales and marketing for rubraca clovis oncology to launch  mln stock offering marketwatch –  pm et  clovis oncology announces proposed offering of common stock business wire –  pm et  clovis oncology inc clvs announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately  million us stockswall st at record highs on technology health stocks strength reuters –  pm et   feds dudley says tight labor market should push inflation up  biogen clovis boost healthcare indexes  investors flood back to technology  indexes up dow  pct sp  pct nasdaq  pct by sinead carew us stockswall st set to open higher as beaten down tech stocks rebound reuters –  am et   feds dudley says tight labor market should push inflation up  retail stocks higher after being roiled last week  futures up dow  pts sp  pts nasdaq  pts by tanya agrawal us stocks looked set to open higher on monday as investors snapped up beaten down technology and retail stocks clovis oncology stock surges  on positive latestage cancer trial results marketwatch –  am et  clovis oncology inc clvs shares surged  in premarket trade monday after the company said its latestage trial for a cancer drug met its primary endpoint and a key secondary endpoint clovis said it plans to try for food and drug administration approval for the drug rucaparib within the next four months for second line and later maintenance treatment for women with platinumsensitive ovarian cancer who have responded to their most recent platinum therapy clovis oncologys stock soars  premarket after positive phase  trial results marketwatch –  am et  us stocksfutures higher as beaten down tech stocks rebound reuters –  am et   futures up dow  pts sp  pts nasdaq  pts us stock index futures were higher on monday with investors snapping up beaten down technology and retail stocks  the sp technology sector is coming off its second straight week of declines triggered mainly due to stretched valuations and investors moving money to other sectors page page   next  todays and upcoming events aug  clvs to announce q earnings after market confirmed aug  clvs earnings conference call at  pm listen past events last  days jun  shareholders meeting data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe clovis oncology inc clvs earns market perform rating from analysts at oppenheimer holdings inc  american banking news home get email updates about disclaimer contact privacy policy   business news us news world news stock ratings analysts upgrades analysts downgrades analysts eps estimates analysts price targets analysts new coverage corporate earnings earnings results earnings guidance earnings previews dividends insider trades options press releases clovis oncology inc  get news  ratings daily enter your email address below to get the latest news and analysts ratings for clovis oncology inc with our free daily email newsletter recent stories michael s cuffe sells  shares of hca holdings inc nysehca stock mercer international inc merc major shareholder peter r kellogg buys  shares a networks inc nyseaten ceo sells  in stock finjan holdings inc fnjn major shareholder sells  in stock alliancebernstein holding lp ab coo sells  in stock insider selling alliancebernstein holding lp nyseab coo sells  shares of stock david l hatcher sells  shares of kmg chemicals inc nysekmg stock kmg chemicals inc kmg major shareholder sells  in stock john p bailey sells  shares of elf beauty inc nyseelf stock earthstone energy inc este evp robert john anderson sells  shares stuart i oran sells  shares of fcb financial holdings inc nysefcb stock papa murphy’s holdings inc frsh major shareholder buys  in stock old national bancorp nasdaqonb insider john r kamin sells  shares edmond macri sells  shares of wayfair inc w stock ascent capital group inc nasdaqascma major shareholder sells  in stock keysight technologies inc keys svp michael gasparian sells  shares insider selling wayfair inc nysew coo sells  shares of stock grubhub inc grub cfo sells  in stock vertex pharmaceuticals incorporated vrtx cmo sells  in stock hr block inc nysehrb svp sells  in stock clovis oncology inc clvs earns market perform rating from analysts at oppenheimer holdings inc june rd  •  comments • filed under • by abmn staff filed under analysts new coverage • market news tweet analysts at oppenheimer holdings inc assumed coverage on shares of clovis oncology inc nasdaqclvs in a research note issued to investors on friday the firm set a “market perform” rating on the biopharmaceutical company’s stock clvs has been the topic of a number of other research reports piper jaffray companies set a  price objective on shares of clovis oncology and gave the company a “buy” rating in a research note on tuesday march th morgan stanley restated an “overweight” rating and issued a  price target on shares of clovis oncology in a research report on tuesday may nd valuengine upgraded shares of clovis oncology from a “sell” rating to a “hold” rating in a research report on friday june nd goldman sachs group inc the lifted their price target on shares of clovis oncology from  to  and gave the stock a “neutral” rating in a research report on wednesday march th finally credit suisse group lifted their price target on shares of clovis oncology from  to  and gave the stock an “outperform” rating in a research report on thursday february rd eight analysts have rated the stock with a hold rating ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock the company has a consensus rating of “buy” and an average target price of  get clovis oncology inc alerts clovis oncology nasdaqclvs opened at  on friday the firm’s day moving average price is  and its  day moving average price is  clovis oncology has a week low of  and a week high of  the firm’s market cap is  billion clovis oncology nasdaqclvs last announced its quarterly earnings results on wednesday may rd the biopharmaceutical company reported  eps for the quarter beating the consensus estimate of  by  the firm had revenue of  million during the quarter compared to analyst estimates of  million on average equities analysts anticipate that clovis oncology will post  earnings per share for the current year trademark violation notice this story was first posted by american banking news and is the property of of american banking news if you are reading this story on another website it was illegally stolen and republished in violation of us and international copyright  trademark legislation the original version of this story can be viewed at httpswwwamericanbankingnewscomclovisoncologyincclvsearnsmarketperformratingfromanalystsatoppenheimerholdingsinchtml in other news insider gillian c iversread sold  shares of the firm’s stock in a transaction on thursday june th the shares were sold at an average price of  for a total transaction of  following the transaction the insider now owns  shares in the company valued at approximately  the transaction was disclosed in a legal filing with the securities  exchange commission which can be accessed through the sec website insiders have sold a total of  shares of company stock worth  in the last  days  of the stock is owned by insiders several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock pnc financial services group inc increased its position in shares of clovis oncology by  in the first quarter pnc financial services group inc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period clough capital partners l p increased its position in shares of clovis oncology by  in the first quarter clough capital partners l p now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period dekabank deutsche girozentrale increased its position in shares of clovis oncology by  in the fourth quarter dekabank deutsche girozentrale now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period rhumbline advisers increased its position in shares of clovis oncology by  in the third quarter rhumbline advisers now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period finally ladenburg thalmann financial services inc increased its position in shares of clovis oncology by  in the fourth quarter ladenburg thalmann financial services inc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period institutional investors and hedge funds own  of the company’s stock clovis oncology company profile clovis oncology inc is a biopharmaceutical company focused on acquiring developing and commercializing anticancer agents in the united states europe and other international markets the company’s product candidates include rociletinib rubraca rucaparib and lucitanib rucaparib is an oral small molecule poly adenosine diphosphate adpribose polymerase parp inhibitor of parp parp and parp approved as a monotherapy for the treatment of patients with deleterious breast cancer brca human genes associated with the repair of damaged deoxyribonucleic acid dna mutation germline andor somatic associated advanced ovarian cancer receive news  ratings for clovis oncology inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for clovis oncology inc and related companies with marketbeatcoms free daily email newsletter leave a reply click here to cancel reply name required mail will not be published required website wordpress hashcash needs javascript to work but your browser has javascript disabled your comment will be placed in moderation  copyright american banking and market news  all rights reserved privacy policy and disclosures  about  advertising  contact content on this website is not meant to be a recommendation or an offer to buy or sell any security click here to read our full disclaimer gillian c iversread sells  shares of clovis oncology inc nasdaqclvs stock  daily political home aboutcontact columnists privacy policy headlines politics nation world issues economy finance clovis oncology inc  get news  ratings daily enter your email address below to get the latest news and analysts ratings for clovis oncology inc with our free daily email newsletter follow dailypolitical     latest news itv plc itv receives “neutral” rating from j p morgan chase  co paul s dickson sells  shares of vivint solar inc nysevslr stock gillian c iversread sells  shares of clovis oncology inc nasdaqclvs stock ken moseley sells  shares of bellicum pharmaceuticals inc nasdaqblcm stock dwight steffensen sells  shares of synnex corporation nysesnx stock legendary investments plc leg given “speculative buy” rating at beaufort securities majesco nysemktmjco given a  price target at maxim group agree realty corporation nyseadc now covered by analysts at canaccord genuity america movil sab de cv nyseamx downgraded to strong sell at zacks investment research imperial capital initiates coverage on caesars entertainment corporation nasdaqczr avalonbay communities inc nyseavb price target raised to  at barclays plc  shares in advanced energy industries inc aeis acquired by hightower advisors llc credit suisse ag boosts stake in post holdings inc post tudor investment corp et al has  stake in tailored brands inc nasdaqtlrd enanta pharmaceuticals inc nasdaqenta shares sold by tudor investment corp et al hospitality properties trust nasdaqhpt shares sold by tudor investment corp et al tudor investment corp et al cuts stake in allstate corporation the nyseall glenmede trust co na has  stake in federal realty investment trust nysefrt credit suisse ag acquires  shares of coherent inc cohr western refining logistics lp wnrl shares sold by credit suisse ag gillian c iversread sells  shares of clovis oncology inc nasdaqclvs stock july th    comments  filed under  by patrick bannon filed under finance  insider trades tweet clovis oncology inc nasdaqclvs insider gillian c iversread sold  shares of clovis oncology stock in a transaction dated monday july th the shares were sold at an average price of  for a total transaction of  following the sale the insider now directly owns  shares in the company valued at approximately  the sale was disclosed in a legal filing with the sec which is available at this link clovis oncology inc nasdaqclvs opened at  on wednesday the stock’s market capitalization is  billion clovis oncology inc has a one year low of  and a one year high of  the firm has a day moving average of  and a  day moving average of  clovis oncology nasdaqclvs last released its quarterly earnings results on wednesday may rd the biopharmaceutical company reported  earnings per share for the quarter beating analysts’ consensus estimates of  by  the firm had revenue of  million during the quarter compared to the consensus estimate of  million on average equities research analysts anticipate that clovis oncology inc will post  earnings per share for the current fiscal year trademark violation warning this news story was originally posted by daily political and is owned by of daily political if you are reading this news story on another domain it was illegally copied and republished in violation of us  international trademark and copyright law the legal version of this news story can be accessed at httpswwwdailypoliticalcomgillianciversreadsellssharesofclovisoncologyincnasdaqclvsstockhtml several hedge funds have recently added to or reduced their stakes in clvs federated investors inc pa purchased a new stake in clovis oncology during the fourth quarter worth  renaissance technologies llc purchased a new stake in clovis oncology during the fourth quarter worth  two sigma investments lp purchased a new stake in clovis oncology during the fourth quarter worth  guggenheim capital llc purchased a new stake in clovis oncology during the fourth quarter worth  finally ladenburg thalmann financial services inc boosted its stake in clovis oncology by  in the fourth quarter ladenburg thalmann financial services inc now owns  shares of the biopharmaceutical company’s stock worth  after buying an additional  shares in the last quarter institutional investors and hedge funds own  of the company’s stock a number of equities research analysts have recently weighed in on the stock zacks investment research lowered shares of clovis oncology from a “buy” rating to a “hold” rating in a research note on thursday july th gabelli assumed coverage on shares of clovis oncology in a research note on friday july th they set a “buy” rating and a  target price on the stock oppenheimer holdings inc began coverage on shares of clovis oncology in a research note on friday june rd they set a “market perform” rating on the stock cann began coverage on shares of clovis oncology in a research report on thursday june nd they set a “market perform” rating for the company finally suntrust banks inc reissued a “buy” rating on shares of clovis oncology in a research report on thursday june nd eight investment analysts have rated the stock with a hold rating eleven have issued a buy rating and one has assigned a strong buy rating to the company the company has an average rating of “buy” and a consensus price target of  about clovis oncology clovis oncology inc is a biopharmaceutical company focused on acquiring developing and commercializing anticancer agents in the united states europe and other international markets the company’s product candidates include rociletinib rubraca rucaparib and lucitanib rucaparib is an oral small molecule poly adenosine diphosphate adpribose polymerase parp inhibitor of parp parp and parp approved as a monotherapy for the treatment of patients with deleterious breast cancer brca human genes associated with the repair of damaged deoxyribonucleic acid dna mutation germline andor somatic associated advanced ovarian cancer receive news  ratings for clovis oncology inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for clovis oncology inc and related companies with marketbeatcoms free daily email newsletter  comment on this post click here to cancel reply name required mail will not be published required website wordpress hashcash needs javascript to work but your browser has javascript disabled your comment will be placed in moderation latest news jeff sessions spoke of resigning after tensions increase with trump president trump’s tweets complicate already complicated week world leaders very critical of paris agreement decision by trump aide to president trump resigns with more expected scudclass missile launched by north korea  dailypolitical llc  all rights reserved privacy policy  about  columnists  contact gillian iversread  aventis pharmaceuticals  inc  zoominfocom